surmount-1 tirzepatide trial obesity without diabetes Gastrointestinal tolerability and weight reduction associated with in adults with or overweight with and type 2 in the SURMOUNT‐1 to ‐4 trials - Rubino - 2025 tirzepatide surmount once weekly for

Elevated NNMT is a consistent feature in obesity research across species, making it a key area of preclinical investigation

Dose reductions may be necessary if side effects occur, whilst escalation may be considered if glycaemic or weight management targets are not met on the current dose

Up to 50% of weight lost from muscle

Greater LAC reductions were also found in women who had experienced childhood trauma

* Melatonin - Improves scalp hair density and controls hair shaft thickness

There was a one-month increase of 18.6% in first-time AOM prescribing between December 2024 (when first-time AOMs accounted for 0.34% of all prescriptions) and January 2025 (when first-time AOMs accounted for 0.41% of all prescriptions)